INTRODUCTION
When red blood cells are damaged within the vascular compartment, hemoglobin (Hb) escapes into the plasma, dimerizes, and is rapidly bound by haptoglobin (Hp). Scavenging of Hb by Hp is critical for preventing Hb-mediated oxidative damage. Hp is an acute phase, plasma-born glycoprotein that is produced mainly by hepatocytes, but also by other cell types including adipocytes and lung cells, and is well known for its ability to tightly bind free Hb following its release from erythrocytes [1] . Hp plasma concentrations are high, ranging from 0.3 to 3.0 mg/mL, yielding a Hp/Hb molar ratio of 400:1 and allowing effective Hb scavenging. This activity of Hp is important for the prevention of iron loss via Hb filtration by the glomeruli and renal damage. Following its formation, Hb/Hp complex is taken up by various scavenger receptors in the liver and other tissues. One such receptor is the Cluster of Differentiation 163 (CD163) receptor, present on macrophages and Kupffer cells. The CD163 receptor strongly binds the Hb/Hp complex and facilitates its endocytosis and degradation [2] . As Hps are not recycled, severe hemolytic diseases result in rapid Hp depletion and rapid accumulation of free heme. Hemopexin (Hx) is an acute phase glycoprotein that is able to bind an equimolar amount of heme with high affinity [3] . Many types of cells synthesize Hx including hepatic parenchymal cells, ganglionic and photoreceptor cells of the retina, kidney mesangial cells, and cells in the central and peripheral nervous system [4] [5] [6] . In adults, the serum Hx concentration ranges from 0.40 to 1.5 mg/mL, and the level of Hx increases in response to high concentrations of free heme. Hx scavenges free heme, and the resultant heme-Hx complex is taken up by the liver through receptor-mediated endocytosis [7] . CD91/low density lipoprotein receptorrelated protein is the scavenger receptor identified for scavenging the heme-Hx complex from circulation to prevent heme-mediated tissue damage [7] .
Watanabe et al. [8] reported that Hb is associated with HDL in mouse models of atherosclerosis. Watanabe et al. [8] demonstrated that Hb when associated with HDL is predominantly in the oxyHb form and can effectively consume nitric oxide and contract arterial vessels ex vivo [8] . In a subsequent study, Watanabe et al. [9] reported that Hb scavenger proteins, Hp and Hx are significantly increased in the apoA-I-containing particles of HDL both in mouse models of atherosclerosis and in coronary heart disease (CHD) patients, when compared with their wild-type counterparts, respectively. Atherosclerosis is the leading cause of morbidity and mortality in Western society. Studies in both mice and humans suggest that the anti-inflammatory or proinflammatory nature of HDL may be a more sensitive predictor of the risk for CHD events than HDL-cholesterol levels alone. Watanabe et al. [9] further demonstrated that the association of Hb, Hp, and Hx proteins with HDL positively correlates with inflammatory properties of HDL and systemic inflammation in CHD patients. Watanabe et al. [9] showed that HDL from Hp À/À mice under atherogenic conditions does not accumulate Hb and is anti-inflammatory whereas HDL from Hx À/À mice was proinflammatory, indicating a novel protective role of Hx in the inflammatory properties of HDL in atherogenic mice. These studies suggested for the first time that the Hb/Hx/Hp pathway, in part, modulates the inflammatory properties of HDL in both mice and humans, and the dissociation of Hb/Hp complex from apoA-I containing particles of HDL may be a novel target for the treatment of CHD and other chronic inflammatory diseases.
The role of Hx and Hp in atherosclerosis has not been directly evaluated to date. In this article, we will discuss some recent publications that underscore the importance of Hx therapy in several inflammatory conditions including atherosclerosis.
Hemopexin is required for heme-dependent activation of heme oxygenase 1
During intravascular or extravascular hemolysis, Hx binds and transports cytotoxic-free heme, to hepatocytes and macrophages where it can be efficiently catabolized. The heme that is transported from the bloodstream to the liver and macrophages by Hx is catabolized by anti-inflammatory gene, heme oxygenase 1 (HO-1) [10, 11] . Heme has been shown to induce the expression of HO-1 by inactivating the transcription repressor Bach1 through direct binding [12 & ]. However, the source of heme for the regulation of the Bach1-HO-1 axis had been unclear. As extracellular heme exists as a complex with Hx in serum under the physiological conditions, Hada et al. [12 & ] examined the effects of (recombinant) rHx-bound heme on HO-1 expression and Bach1 in Hepa-1c1c7 liver cells as well as human peripheral blood monocytic cell line macrophage cells. Hada et al. demonstrated that rHxbound heme was internalized into the cells via endocytosis, resulting in HO-1 expression and inactivation of Bach1, suggesting that induction of HO-1 expression is Hx-dependent and Hx plays an antiatherogenic role. It should be noted that Hx has also been shown to exert antiatherogenc activity in a non-HO-1-dependent mechanism [13] . Liang et al. [13] reported that Hx limits Toll-like receptor (TLR) and TLR2 agonist-induced macrophage cytokine production directly through a mechanism distinct from HO-1 that does not involve binding and clearing of free heme [13] .
Hemopexin levels predict hemolytic diseases and septic shock
Heme is an essential molecule for living aerobic organisms and is involved in a remarkable array of diverse biological processes and disease conditions. Hemolytic diseases such as sickle cell disease and b-thalassemia are characterized by enhanced
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Hb/Hx/Hp pathway, in part, modulates the inflammatory properties of HDL in both atherosclerotic mice and humans.
HDL from Hx-null mice is proinflammatory indicating a novel protective role of Hx in the inflammatory properties of HDL.
Hx has been shown to modulate the expression of the antioxidant enzyme HO-1.
Acute or chronic inflammatory conditions such as cerebral ischemia, septic shock, and cardiovascular disease are aggravated in the absence of Hx.
Hx therapy against heme mediated oxidative stress can improve inflammatory conditions. intravascular hemolysis resulting in heme-catalyzed reactive oxygen species (ROS) generation, which leads to endothelial dysfunction and oxidative damage [14] . In addition, low serum Hx levels are related to sepsis severity and can indicate poor prognosis for septic shock patients [15 && ]. Jung et al. [15 && ] measured the concentrations of Hx in a rat model featuring distinct grades of severity of endotoxemia and in patients who survived and did not survive septic shock. Jung et al. [15 && ] showed that the levels of Hx are substantially lower during severe endotoxemia than during mild endotoxemia in the rat model. In addition, serum Hx levels are dissimilar in patients under septic conditions of distinct severity and, the initial serum Hx concentration in nonsurvivors is significantly lower than in survivors. Jung et al. [15 && ] concluded that serum Hx concentration can help predict the 28-day mortality among septic shock patients and suggested that a diminished level of Hx might be associated with poor prognosis in severe sepsis validating previous reports by Larsen et al. [16] . Moreover, previous studies also reported that Hx can potently suppress the synergistic effect exerted by heme and Hb on sterile and septic inflammatory stimuli such as High Mobility Group Box 1 and lipopolysaccharide [17] [18] [19] .
Hemopexin administration protects cerebral ischemic injury
Free heme is released from methemoglobin following cerebral ischemia reperfusion and represents a toxic component in the peripheral blood. Hx, due to its high binding affinity to heme and an efficient scavenger of heme in overloaded peripheral blood, was suggested to be neuroprotective. Studies by Li et al. [20] reported that Hx-null mice sustain greater infarct volumes and behavioral deficits than their wild-type counterparts in a model of transient middle cerebral artery occlusion, indicating its neuroprotective role against stroke-related damage [20] . However, it has not been clear how Hx exerted its neuropotective role until a recent study by Dong et al. [21] who investigated the expression of Hx in the normal rat brain by immunofluorescent staining. Dong et al. [21] showed that Hx is mainly expressed in the neurons and a small portion of astrocytes after a short-term middle cerebral artery occlusion followed by 24-h reperfusion in the rat brain. Dong et al. [21] further demonstrated that administration of exogenous Hx at the onset of reperfusion dose-dependently reduced the infarct volumes and improved the outcome of cerebral ischemia-reperfusion injury. These studies [21] confirmed the neuroprotective effects of Hx and provide new insights into the potential therapeutic role of Hx in cerebral ischemia.
Hemopexin administration improves cardiovascular function
Circulating ferrous heme (on Hb) is considered as one of the important pathogenic factors in cardiovascular disease. Increased circulating ferrous heme containing Hb scavenges nitric oxide, a potent vasodilator [22] ; promotes the generation of ROS, which leads to endothelial activation [23] ; and induces smooth muscle proliferation [24] , contributing further to cardiovascular disease [25] . Using a model of heme overload in Hx-null mice, Vinchi et al. [14] demonstrated that when excess heme is bound to Hx, ROS production and adhesion molecule expression are reduced and nitric oxide availability is increased. Using b-thalassemia and sickle cell disease mouse models of hemolytic diseases, Vinchi et al. [14] discovered that Hx therapy preserves cardiovascular function and normalizes blood pressure by promoting heme recovery and hepatic detoxification of heme mainly through the induction of HO-1 activity. The authors suggested that Hx treatment is a promising novel therapy to protect against heme-induced cardiovascular dysfunction in hemolytic diseases [14] .
Hemopexin and heme-iron recycling
Hx limits iron access to microorganisms mediating heme-iron recycling. Fiorito et al. [26] recently demonstrated increased iron levels in the duodenum of Hx-null mice due to increased iron uptake by enterocytes and storage in ferritins. The study reported that Hx deficiency resulted in enhanced heme catabolism in the duodenum by inducing HO-1 activity. The transfer of iron from the enterocytes to the liver was unaffected indicative of abnormal levels of iron deposits in the duodenal mucosa. In addition, they showed that absence of Hx did not affect the expression of iron transporters in the duodenum cells despite increased iron accumulation. This provides new insights to the understanding of body iron homeostasis and possibly at identifying strategies to increase/reduce iron absorption in the therapy of metabolic disorders of iron deficiency and overload, respectively [26] .
Hemopexin in autoimmune disorders
Hx levels increase and remain high in experimental autoimmune encephalomyelitis (EAE) mice, the mouse model of multiple sclerosis. EAE induced in Hx knockout mice, developed EAE clinically earlier, and exacerbated compared with mice having Hx due to a large amount of CD4 þ -infiltrating T cells. Hx-null mice developed severe EAE due to a greater number of infiltrating and circulating Th17 cells. Hx therapy in Hx-null mice before EAE induction reduced the Th17 expansion, as well as disease severity, and was comparable with those of wildtype mice. Taken together, these data indicate that Hx has a negative regulatory effect in Th17-mediated inflammation and propose Hx's therapy to limit the expansion of this cell subset in inflammatory and autoimmune diseases [27] .
CONCLUSION
Hx is implicated in a number of inflammatory diseases. Heme scavenging appears to be the primary mechanism by which Hx protects against oxidative stress and related inflammatory disorders. Hx has been shown to modulate the expression of the antiinflammatory protein HO-1 via mechanisms that include the removal and/or inactivation of transcription suppressors. Many inflammatory conditions including cerebral ischemic function, septic shock, and cardiovascular function are exacerbated in Hx deficiency. Recent studies in animal models underscore the importance of Hx therapy against heme and oxidative stress-mediated inflammatory conditions. Future studies should be directed to test Hx therapy in humans.
